Bupivacaine and Fentanyl — Competitive Intelligence Brief

Bupivacaine and Fentanyl (Bupivacaine and Fentanyl) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with opioid analgesic combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl) Anesthesia and Pain Management Small molecule

Target snapshot

Bupivacaine and Fentanyl (Bupivacaine and Fentanyl) — Bnai Zion Medical Center. Bupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine and Fentanyl TARGET	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Levobupivacaine and Fentanyl	Levobupivacaine and Fentanyl	Hamad Medical Corporation	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor
Naropin 0.1% cum sufentanil	Naropin 0.1% cum sufentanil	Bent Gymoese Jorgensen	phase 3	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with opioid analgesic combination class)

1. Bent Gymoese Jorgensen · 1 drug in this class
2. Bnai Zion Medical Center · 1 drug in this class
3. Conrad Arnfinn Bjørshol · 1 drug in this class
4. Hamad Medical Corporation · 1 drug in this class
5. National Institute for Tuberculosis and Lung Diseases, Poland · 1 drug in this class